Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$25.17 USD
-1.18 (-4.48%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $25.16 -0.01 (-0.04%) 6:52 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Akero Therapeutics, Inc. (AKRO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$45.80 | $60.00 | $30.00 | 73.81% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Akero Therapeutics, Inc. comes to $45.80. The forecasts range from a low of $30.00 to a high of $60.00. The average price target represents an increase of 73.81% from the last closing price of $26.35.
Analyst Price Targets (10)
Broker Rating
Akero Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.18 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.18 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, 10 are Strong Buy, representing 90.91% of all recommendations. A month ago, Strong Buy represented 90.91%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.18 | 1.18 | 1.18 | 1.20 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/11/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
6/11/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
6/10/2024 | Cantor Fitzgerald & Co | Prakhar Agrawal | Strong Buy | Strong Buy |
5/15/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
5/13/2024 | Canaccord Genuity | Edward H Nash | Strong Buy | Strong Buy |
5/13/2024 | LifeSci Capital | Rami Katkhuda | Strong Buy | Strong Buy |
3/5/2024 | UBS | Eliana Merle | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.18 |
ABR (Last week) | 1.18 |
# of Recs in ABR | 11 |
Average Target Price | $45.80 |
LT Growth Rate | 8.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 88 of 253 |
Current Quarter EPS Est: | -0.90 |